TipRanks
Go Ultimate55% OFF

Medius Holdings Co., Ltd. (3154) AI Stock Analysis

JP:3154

Medius Holdings Co., Ltd.

(TSE/TYO:3154)

Select Model
Rating:50Neutral
Price Target:JPY 780.00â–²(5.83% Upside)
Action:reiterated
Date:08/17/26

Medius Holdings receives a neutral overall score heavily weighed down by deteriorating profitability and negative free cash flows, despite consistent revenue expansion. Weak technical indicators suggest continued bearish momentum, though a reasonable valuation and a 2.56% dividend yield offer a buffer. Management's ability to improve operating margins and cash conversion will be critical for a more positive outlook.

Positive Factors
Steady Revenue GrowthSustained revenue expansion indicates resilient demand for medical devices and related supplies. Serving hospitals and clinics provides an established healthcare customer base, supporting business continuity over the medium term.
Negative Factors
Compressed ProfitabilityVery thin net margins and declining returns on equity leave limited room to absorb cost inflation or execution errors. Persistently weak profitability could constrain reinvestment, reduce shareholder returns and limit the benefits of revenue growth.

Medius Holdings Co., Ltd. (3154) vs. iShares MSCI Japan ETF (EWJ)

-10%-5%0%5%10%15%20%25%JP:3154-4.53%EWJ+15.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
JPY 16.39B
Dividend Yield
2.71%
Average Volume (3M)
27.52K
Price to Earnings (P/E)
17.4
Beta (1Y)
0.56
Revenue Growth
4.73%
EPS Growth
-31.38%
Country
Japan
Employees
2,716
Sector
Healthcare
Sector Strength
51
Industry
Medical - Distribution

Medius Holdings Co., Ltd. Business Overview & Revenue Model

Company Description

Medius Holdings Co., Ltd. is a Japanese enterprise deeply embedded in the healthcare sector. The company's operations involve the distribution of a diverse range of medical devices, encompassing fundamental consumables such as syringes and gauze, as...

How the Company Makes Money

Medius Holdings primarily makes money through the sale and distribution of medical devices and related medical consumables to healthcare providers (e.g., hospitals and clinics). Revenue is generated when the company procures products from manufacture...

Medius Holdings Co., Ltd. Financial Statement Overview

Summary

The company shows robust top-line revenue growth and maintains a conservative balance sheet with decreasing debt levels. However, this is significantly offset by systemic profitability issues, declining net income, razor-thin profit margins, and a recent shift to negative free cash flow.

Income Statement

45Neutral

Balance Sheet

65Positive

Cash Flow

40Negative
Financial statement breakdown
BreakdownTTMJun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue302.34B302.34B288.69B259.79B239.05B221.69B
Gross Profit35.00B35.82B33.30B31.09B29.31B27.42B
EBITDA4.33B4.01B4.77B3.86B4.27B3.80B
Net Income944.09M944.09M1.38B1.12B1.50B1.87B
Balance Sheet
Total Assets112.59B112.59B113.54B115.34B97.73B93.15B
Cash, Cash Equivalents and Short-Term Investments10.05B10.05B14.33B13.64B10.33B9.11B
Total Debt18.39B18.39B21.89B24.57B19.70B17.98B
Total Liabilities91.85B91.85B93.06B95.60B79.15B75.84B
Stockholders Equity20.74B20.74B20.48B19.74B18.57B17.31B
Cash Flow
Free Cash Flow0-373.71M5.26B261.12M300.65M-8.49B
Operating Cash Flow0374.23M7.01B1.92B1.22B-3.90B
Investing Cash Flow0-1.26B-2.51B-2.67B-862.94M-4.82B
Financing Cash Flow0-3.40B-3.47B4.01B862.90M5.21B

Medius Holdings Co., Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price737.00

Price Trends

50DMA780.96Negative
100DMA792.25Negative
200DMA798.10Negative

Market Momentum

MACD-11.85Positive
RSI33.82Neutral
STOCH7.27Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3154, the sentiment is Negative. The current price of 737.00 is below the 20-day moving average (MA) of 762.60, below the 50-day MA of 780.96, and below the 200-day MA of 798.10, indicating a bearish trend. The MACD of -11.85 indicates Positive momentum. The RSI at 33.82 is Neutral, neither overbought nor oversold. The STOCH value of 7.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:3154.

Medius Holdings Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:3154 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:7747JP:774782OutperformJPY 973.21B30.4219.88%1.32%21.16%156.97%
JP:7730JP:773079OutperformJPY 149.06B20.59―2.71%10.18%55.86%
JP:7979JP:797966NeutralJPY 82.07B13.25―2.65%6.53%52.32%
JP:7716JP:771660NeutralJPY 250.99B102.861.89%2.04%14.87%-55.19%
JP:7702JP:770256NeutralJPY 10.63B-15.18―3.91%-5.34%-152.53%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:3154JP:315450NeutralJPY 16.39B17.36―2.71%4.73%-31.38%

* Healthcare Sector Average

Performance Comparison

0%20%40%60%JP:3154JP:7747JP:7716JP:7702JP:7730JP:7979Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
JP:3154 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:3154Medius Holdings Co., Ltd.737.00-41.82-5.37%
JP:7747Asahi Intecc Co 3668.001252.6951.86%
JP:7716Nakanishi 1421.00424.2042.56%
JP:7702JMS Co., Ltd.435.0020.995.07%
JP:7730Mani, Inc.1513.0074.815.20%
JP:7979Shofu Inc.2300.00478.6426.28%

Medius Holdings Co., Ltd. Corporate Events

Medius Holdings Sees Profit Drop but Projects Earnings Recovery in FY2027

Aug 12, 2026

Medius Holdings Co., Ltd., a Tokyo Prime Market-listed company, reported consolidated net sales of ¥302.3 billion for the fiscal year ended June 30, 2026, a 4.7% increase year on year, while operating profit and ordinary profit declined slightly...

Medius Holdings Announces Corrections to Previously Released Financial Results

Aug 12, 2026

Medius Holdings Co., Ltd., a Prime Market-listed Japanese company, has notified investors that previously released financial results contain errors that require correction. The firm has directed stakeholders to its Japanese disclosure materials for d...

Medius Holdings Names Hiroyuki Akutagawa as New President and Representative Director

Jun 25, 2026

Medius Holdings Co., Ltd. announced that President and Representative Director Yasuhiko Ikeya will resign from his role effective August 1, 2026, due to health reasons, and will assume the post of non-representative Chairman. The Board of Directors h...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 17, 2026